$CRL is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 4 active Congressional signals mentioning $CRL, including 4 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
$CRL is currently facing 4 active congressional signals tracked by HillSignal. With 1 bullish, 1 neutral, and 2 bearish signals, the average legislative impact score is 4.0/10. Key sectors affected include Healthcare and Defense. Recent major catalysts include Medical Research for Our Troops Act and CARGO Act of 2025. Below is the complete tracker of government activity affecting $CRL’s market performance.
H.R. 6993, the BEACON Act of 2026, establishes a grant program within the Department of Veterans Affairs (VA) to fund research into neurorehabilitation treatments for chronic mild Traumatic Brain Injury (mTBI) in veterans. This creates a new funding stream for academic institutions, nonprofit organizations, and specialized healthcare providers focused on TBI research and treatment. The bill does not address H-1B or L-1 visas.
Impact: 3/10(Early stage (action not classified))HR6993Congressional Bill
The CARGO Act of 2025 prohibits the National Institutes of Health (NIH) from funding animal research outside the United States, redirecting approximately $2.2 billion in research grants domestically. This legislation creates a significant headwind for contract research organizations (CROs) with substantial international animal research operations and benefits domestic U.S. animal research facilities.
The 'Medical Research for Our Troops Act' restores $1.181 billion to the Defense Health Agency for medical research, directly increasing funding for military health R&D. This benefits companies involved in clinical research, medical device manufacturing, and pharmaceutical development for defense applications. The bill ensures program continuity and adherence to specific funding allocations from previous appropriations.
Impact: 5/10(Early stage (action not classified))HR3906Congressional Bill
HR7165 mandates inspections of foreign laboratories conducting biomedical research, directly increasing operational costs and causing delays for Contract Research Organizations (CROs) and pharmaceutical companies with significant international operations. This bill creates a new regulatory burden, reducing profit margins and slowing drug development timelines.
Impact: 4/10(Early stage (action not classified))HR7165Congressional Bill